These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 33134776

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Long-Term Safety and Efficacy of Nonacog Beta Pegol (N9-GP) Administered for at Least 5 Years in Previously Treated Children with Hemophilia B.
    Carcao M, Kearney S, Lu MY, Taki M, Rubens D, Shen C, Santagostino E.
    Thromb Haemost; 2020 May; 120(5):737-746. PubMed ID: 32369845
    [Abstract] [Full Text] [Related]

  • 5. Nonacog beta pegol in previously treated children with hemophilia B: results from an international open-label phase 3 trial.
    Carcao M, Zak M, Abdul Karim F, Hanabusa H, Kearney S, Lu MY, Persson P, Rangarajan S, Santagostino E.
    J Thromb Haemost; 2016 Aug; 14(8):1521-9. PubMed ID: 27174727
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of rFIXFc versus N9-GP Prophylaxis in Patients with Hemophilia B: Matching-Adjusted Indirect Comparison of B-LONG and PARADIGM 2 Trials.
    Mancuso ME, Eriksson D, Falk A, Hakimi Z, Wojciechowski P, Wdowiak M, Klamroth R.
    J Blood Med; 2023 Aug; 14():427-434. PubMed ID: 37534261
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetics of a novel extended half-life glycoPEGylated factor IX, nonacog beta pegol (N9-GP) in previously treated patients with haemophilia B: results from two phase 3 clinical trials.
    Tiede A, Abdul-Karim F, Carcao M, Persson P, Clausen WHO, Kearney S, Matsushita T, Negrier C, Oldenburg J, Santagostino E, Young G.
    Haemophilia; 2017 Jul; 23(4):547-555. PubMed ID: 28233381
    [Abstract] [Full Text] [Related]

  • 8. Treatment switch to nonacog beta pegol factor IX in hemophilia B: A Canadian cost-consequence analysis based on real-world factor IX consumption and clinical outcomes.
    Iorio A, MacDonald V, Caillaud A, Luckevich MD, Christoffersen P, Matino D, Keepanasseril A, Iserman E, Germini F, Bentley A, Poon MC.
    Res Pract Thromb Haemost; 2023 Mar; 7(3):100106. PubMed ID: 37065846
    [Abstract] [Full Text] [Related]

  • 9. Nonacog beta pegol (N9-GP) in haemophilia B: A multinational phase III safety and efficacy extension trial (paradigm™4).
    Young G, Collins PW, Colberg T, Chuansumrit A, Hanabusa H, Lentz SR, Mahlangu J, Mauser-Bunschoten EP, Négrier C, Oldenburg J, Patiroglu T, Santagostino E, Tehranchi R, Zak M, Karim FA.
    Thromb Res; 2016 May; 141():69-76. PubMed ID: 26970716
    [Abstract] [Full Text] [Related]

  • 10. Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9-GP), a glycoPEGylated recombinant factor IX.
    Collins PW, Møss J, Knobe K, Groth A, Colberg T, Watson E.
    J Thromb Haemost; 2012 Nov; 10(11):2305-12. PubMed ID: 22998153
    [Abstract] [Full Text] [Related]

  • 11. Qualification of a select one-stage activated partial thromboplastin time-based clotting assay and two chromogenic assays for the post-administration monitoring of nonacog beta pegol.
    Tiefenbacher S, Bohra R, Amiral J, Bowyer A, Kitchen S, Lochu A, Rosén S, Ezban M.
    J Thromb Haemost; 2017 Oct; 15(10):1901-1912. PubMed ID: 28772338
    [Abstract] [Full Text] [Related]

  • 12. Switching to nonacog beta pegol in hemophilia B: Outcomes from a Canadian real-world, multicenter, retrospective study.
    Matino D, Iorio A, Keepanasseril A, Germini F, Caillaud A, Carcao M, Hews-Girard J, Iserman E, James P, Lee A, Phua CW, Sun HL, Teitel J, Poon MC.
    Res Pract Thromb Haemost; 2022 Mar; 6(3):e12661. PubMed ID: 35386274
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Measuring factor IX activity of nonacog beta pegol with commercially available one-stage clotting and chromogenic assay kits: a two-center study.
    Bowyer AE, Hillarp A, Ezban M, Persson P, Kitchen S.
    J Thromb Haemost; 2016 Jul; 14(7):1428-35. PubMed ID: 27107268
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Population Pharmacokinetic Modeling Of On-Demand And Surgical Use Of Nonacog Beta Pegol (N9-GP) And rFIXFc Based Upon The paradigm 7 Comparative Pharmacokinetic Study.
    Simpson ML, Kulkarni R, Escuriola Ettingshausen C, Medom Meldgaard R, Cooper DL, Klamroth R.
    J Blood Med; 2019 Jul; 10():391-398. PubMed ID: 32009825
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. FIXing postinfusion monitoring: Assay experiences with N9-GP (nonacog beta pegol; Refixia® ; Rebinyn® ).
    Ezban M, Hermit MB, Persson E.
    Haemophilia; 2019 Jan; 25(1):154-161. PubMed ID: 30664825
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.